Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy

Endometriosis Clinical Trial

— ENDOmiRNA  

Official title:

Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06414720
• Other study ID #: ENDOmiRNA
• Status: Recruiting
• Start date: April 22, 2024
• Est. completion date: May 1, 2025

Study information

• Verified date: May 2024
• Source: University of Udine
• Contact: Matilde Degano, dr
• Phone: 3206173076
• Email: matildedegano[@]rocketmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.

Description:

In recent years, scientific literature has focused on the search for new non-invasive diagnostic tools that can identify patients with endometriosis early and easily, thereby reducing diagnostic delay and enabling the immediate initiation of appropriate treatment. Among these, microRNA (miRNA) is emerging as a promising option. Despite recent progress in this field, a predictive biomarker of response to medical therapy or vice versa, resistance to progesterone in endometriosis, has not yet been identified, including among miRNAs. This study aims, therefore, to identify salivary miRNA signatures specific to endometriosis and differentially expressed between responder and non-responder patients to 2 mg dienogest medical therapy. 90 patients diagnosed with endometriosis attending the Obstetrics and Gynecology Clinic at the Santa Maria della Misericordia Hospital in Udine will be enrolled. The investigators will ask them for a salivary sample before starting the progestin therapy. After 4 months from the beginning, the response will be evaluated. The researchers will evaluate the differences between salivary miRNA of the responders vs non-responders.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: May 1, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

INCLUSION CRITERIA

• Age > 18 years

• Fertile age

• Clinical-ultrasound diagnosis or histological diagnosis of endometriosis

• Informed consent

EXCLUSION CRITERIA

• Pregnancy

• Pre-menarcheal or post-menopausal status

• Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)

• Neoplasia, diabetes, BMI > 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement

• Currently undergoing progestin therapy

Related Conditions & MeSH terms

• Endometriosis

Intervention

Drug:
• Dienogest 2 MG
The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.

Locations

Country	Name	City	State
Italy	University of Udine	Udine	UD

Sponsors (1)

Lead Sponsor	Collaborator
University of Udine

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Bendifallah S, Suisse S, Puchar A, Delbos L, Poilblanc M, Descamps P, Golfier F, Jornea L, Bouteiller D, Touboul C, Dabi Y, Darai E. Salivary MicroRNA Signature for Diagnosis of Endometriosis. J Clin Med. 2022 Jan 26;11(3):612. doi: 10.3390/jcm11030612. — View Citation

Hon JX, Wahab NA, Karim AKA, Mokhtar NM, Mokhtar MH. MicroRNAs in Endometriosis: Insights into Inflammation and Progesterone Resistance. Int J Mol Sci. 2023 Oct 9;24(19):15001. doi: 10.3390/ijms241915001. — View Citation

Zhang P, Wang G. Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms. Int J Mol Sci. 2023 Apr 10;24(8):6992. doi: 10.3390/ijms24086992. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response to the progestin therapy	response to 2 mg dienogest therapy evaluated with NRS (numeric rating scale) scale assessed for acyclic pain, dyspareunia, dyschezia, dysmenorrhea, periovulatory pain	0 (pre-therapy) - 4 months (after therapy)
Primary	changes in quality of life	changes in quality of life assessed with questionnaire SF-36 (Short Form Health Survey 36)	0 (pre-therapy) - 4 months (after therapy)
Primary	differences in salivary miRNoma	Once it is established which patients are responders and which are non-responders, differential salivary miRNAs between the two groups will be identified via sequencing. The miRNA reverse transcription reaction will be performed using the reverse transcription kit TaqMan MicroRNA (Applied Biosystems). The reverse transcription product will be used for Real-time PCR. The small nucleolar RNA RNU6 will be used as an endogenous control. The protocol of Amplification will be carried out using the LightCycler 480 instrument (Roche). For each miRNA, qPCR will be performed in duplicate. The relative expression levels of miRNAs will be calculated using the 2-??Ct method.	sample collection at time 0, analysis after time 4